Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/14/16 | $55,000,000 | Series A |
Third Rock Ventures | undisclosed |
